Journal
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
Volume 48, Issue 5, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0300060520926093
Keywords
Polo-like kinase 1; BI6727; Burkitt lymphoma; FBXW7; C-MYC; PI3K; AKT; mTOR
Funding
- Health and Family Planning Administration of Ningbo [2017C10084]
- Health and Family Planning Commission of Zhejiang province [2016A175]
Ask authors/readers for more resources
Objective BI6727, an ATP-competitive PLK1 inhibitor, has been shown to cause cell death in multi-tumors. This study aimed to investigate the anti-tumor effect and potential molecular mechanism of BI6727 in human Burkitt lymphoma (BL) cell lines. Methods We assessed polo-like kinase 1 (PLK1) expression in BL patient tissues and cells, also investigated the cytotoxic effect using CCK8 assay and flow cytometry. In addition, western blotting and real-time polymerase chain reaction (RT-PCR) assays were used to explore the molecular mechanisms of BI6727 in human BL cell lines. Results PLK1 was overexpressed in BL cells compared with normal cells. The PLK1 inhibitor BI6727 reduced activated PLK1 expression and caused mitotic arrest in BL cells. Additionally, BI6727 suppressed cellular proliferation and induced apoptosis in BL cell lines. BI6727 treatment also decreased C-MYC protein and mRNA expression, blocked the PI3K/AKT/mTOR signaling pathway, and stabilized the FBXW7 protein. Conclusions Our findings explained a potential molecular mechanism of BI6727 in BL cells and suggested that BI6727 might be a new therapeutic agent for BL in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available